Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders

Table 1 Anagraphical and clinical information characteristics of the enrolled patients

Characteristics	N	(%)	aGvHD	No aGvHD	P
Age (years)					ns
Mean	8.4		8.2	9.0
Range	1–21		2–19	1–21
Female Sex	12	33.3	6	6
Disease					ns
ALL	14	38.9	7	7
AML	9	25.0	4	5
Thalassemia Major	5	13.9	2	3
SAA	3	8.3	2	1
BDA	3	8.3	2	1
CDA	1	2.8	1	0
ALPS	1	2.8	1	0
Risk^a					ns
High Risk	8	22.2	5	3
Standard Risk	28	77.8	14	14
Graft Source					ns
Unmodified BM	29	80.6	16	13
T-cell Depleted PBSC	6	16.7	2	4
Cord Blood	1	2.8	1	0
Matching HLA					ns
Matched	26	72.2	14	12
Mismatched	10	27.8	5	5
Conditioning Regimen^b					ns
Myeloablative	35	88.9	18	16
Nonmyeloablative	1	11.1	1	0
GvHD Prophylaxis					ns
αβ T-cell and B-cell depletion	6	16.7	3	3
Calcineurin Inhibitor alone	7	19.4	4	3
CI + ATG +/− MTX	21	58.3	11	10
CI + ATG + Prednisone	1	2.8	1	0
CI + Cyclophosphamide post	1	2.8	0	1
GvHD	19	52.8
Mean Day of Onset (days from transplantation)	+ 21
I	5	26.3
II	9	47.4
III	3	15.8
IV	2	10.5
Gut Involvement	6	31.6

Abbreviations: ALL Acute Lymphoblastic Leukemia, AML Acute Myeloid Leukemia, SAA Severe Aplastic Anemia, BDA Blackfan-Diamond Anemia, CDA Congenital Dyserythropoietic Anemia, ALPS Autoimmune Lymphoproliferative Syndrome, BM Bone Marrow, PBSC Peripheral Blood Stem Cells, GvHD Graft-versus-Host Disease, ATG Anti-Thymocyte Globulin, MTX Methotrexate, ns not significant
^aRisk staging: high risk: >1st complete remission (CR) or refractory disease; standard risk: 1st CR or non-malignant disease
^bAs defined by Bacigalupo et al. [50]

ISSN: 1755-8794